Circulating tumour cells (CTCs), identified in numerous cancers including melanoma, are unquestionably considered valuable and useful as diagnostic and prognostic markers. They can be detected at all melanoma stages and may persist long after treatment. A crucial step in metastatic processes is the intravascular invasion of neoplastic cells as circulating melanoma cells (CMCs). Only a small percentage of these released cells are efficient and capable of colonizing with a strong metastatic potential. CMCs' ability to survive in circulation express a variety of genes with continuous changes of signal pathways and proteins to escape immune surveillance. This makes it difficult to detect them; therefore, specific isolation, enrichment and characterization of CMC population could be useful to monitor disease status and patient clinical outcome. Overall and disease-free survival have been correlated with the presence of CMCs. Specific melanoma antigens, in particular MCAM (MUC18/MelCAM/CD146), could be a potentially useful tool to isolate CMCs as well as be a prognostic, predictive biomarker. These are the areas reviewed in the article.

Rapanotti, M.c., Campione, E., Spallone, G., Orlandi, A., Bernardini, S., & Bianchi, L. (2017). Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. CELL DEATH DISCOVERY, 3(17005) [10.1038/cddiscovery.2017.5].

Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146

CAMPIONE, ELENA;SPALLONE, GIULIA;ORLANDI, AUGUSTO;BERNARDINI, SERGIO;BIANCHI, LUCA
2017

Abstract

Circulating tumour cells (CTCs), identified in numerous cancers including melanoma, are unquestionably considered valuable and useful as diagnostic and prognostic markers. They can be detected at all melanoma stages and may persist long after treatment. A crucial step in metastatic processes is the intravascular invasion of neoplastic cells as circulating melanoma cells (CMCs). Only a small percentage of these released cells are efficient and capable of colonizing with a strong metastatic potential. CMCs' ability to survive in circulation express a variety of genes with continuous changes of signal pathways and proteins to escape immune surveillance. This makes it difficult to detect them; therefore, specific isolation, enrichment and characterization of CMC population could be useful to monitor disease status and patient clinical outcome. Overall and disease-free survival have been correlated with the presence of CMCs. Specific melanoma antigens, in particular MCAM (MUC18/MelCAM/CD146), could be a potentially useful tool to isolate CMCs as well as be a prognostic, predictive biomarker. These are the areas reviewed in the article.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - Malattie Cutanee e Veneree
English
Rapanotti, M.c., Campione, E., Spallone, G., Orlandi, A., Bernardini, S., & Bianchi, L. (2017). Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. CELL DEATH DISCOVERY, 3(17005) [10.1038/cddiscovery.2017.5].
Rapanotti, M; Campione, E; Spallone, G; Orlandi, A; Bernardini, S; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
cddiscovery20175.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 1.34 MB
Formato Adobe PDF
1.34 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/185067
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact